These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17321043)

  • 21. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.
    Sharma P; Falk GW; Weston AP; Reker D; Johnston M; Sampliner RE
    Clin Gastroenterol Hepatol; 2006 May; 4(5):566-72. PubMed ID: 16630761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma.
    Larghi A; Lightdale CJ; Ross AS; Fedi P; Hart J; Rotterdam H; Noffsinger A; Memeo L; Bhagat G; Waxman I
    Endoscopy; 2007 Dec; 39(12):1086-91. PubMed ID: 17701854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system).
    Sharma VK; Kim HJ; Das A; Dean P; DePetris G; Fleischer DE
    Endoscopy; 2008 May; 40(5):380-7. PubMed ID: 18459074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barrett's esophagus: pathologic considerations and implications for treatment.
    Rice TW; Mendelin JE; Goldblum JR
    Semin Thorac Cardiovasc Surg; 2005; 17(4):292-300. PubMed ID: 16428035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allelic imbalance of 7q32.3-q36.1 during tumorigenesis in Barrett's esophagus.
    Riegman PH; Burgart LJ; Wang KK; Wink-Godschalk JC; Dinjens WN; Siersema PD; Tilanus HW; van Dekken H
    Cancer Res; 2002 Mar; 62(5):1531-3. PubMed ID: 11888931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities.
    Peters FP; Krishnadath KK; Rygiel AM; Curvers WL; Rosmolen WD; Fockens P; Ten Kate FJ; van Baal JW; Bergman JJ
    Am J Gastroenterol; 2007 Sep; 102(9):1853-61. PubMed ID: 17509033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients.
    Dumot JA; Vargo JJ; Falk GW; Frey L; Lopez R; Rice TW
    Gastrointest Endosc; 2009 Oct; 70(4):635-44. PubMed ID: 19559428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
    Rossi E; Villanacci V; Bassotti G; Casa DD; Missale G; Minelli L; Cestari R
    Diagn Mol Pathol; 2006 Sep; 15(3):125-30. PubMed ID: 16932066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
    Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus.
    Sharma P; Bansal A; Mathur S; Wani S; Cherian R; McGregor D; Higbee A; Hall S; Weston A
    Gastrointest Endosc; 2006 Aug; 64(2):167-75. PubMed ID: 16860063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.
    van Dekken H; Hop WC; Tilanus HW; Haringsma J; van der Valk H; Wink JC; Vissers KJ
    Am J Clin Pathol; 2008 Nov; 130(5):745-53. PubMed ID: 18854267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment.
    Panjehpour M; Coppola D; Overholt BF; Vo-Dinh T; Overholt S
    Anticancer Res; 2008; 28(1B):485-9. PubMed ID: 18383889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens.
    Fahmy M; Skacel M; Gramlich TL; Brainard JA; Rice TW; Goldblum JR; Connor JT; Casey G; Legator MS; Tubbs RR; Falk GW
    Mod Pathol; 2004 May; 17(5):588-96. PubMed ID: 15017433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues.
    Rauser S; Weis R; Braselmann H; Feith M; Stein HJ; Langer R; Hutzler P; Hausmann M; Lassmann S; Siewert JR; Höfler H; Werner M; Walch A
    Clin Cancer Res; 2007 Sep; 13(17):5115-23. PubMed ID: 17785566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy.
    Abela JE; Going JJ; Mackenzie JF; McKernan M; O'Mahoney S; Stuart RC
    Am J Gastroenterol; 2008 Apr; 103(4):850-5. PubMed ID: 18371135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry.
    Kaye PV; Haider SA; Ilyas M; James PD; Soomro I; Faisal W; Catton J; Parsons SL; Ragunath K
    Histopathology; 2009 May; 54(6):699-712. PubMed ID: 19438745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of locus-specific probes for interphase fluorescence in situ hybridisation--application in Barrett's esophagus.
    Doak SH; Saidely D; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
    Exp Mol Pathol; 2004 Aug; 77(1):26-33. PubMed ID: 15215047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.